Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Japan Tobacco PDE7A compound 26
- Development stage
- Unknown
- Lead developer
- Japan Tobacco
01
Overview
Japan Tobacco PDE7A compound 26: sourced facts only. name: "Therefore, starting from a PDE7A/7B dual inhibitor, our investigations led to improved selectivity along with extended metabolic stability, resulting in a novel PDE7A inhibitor 26." [PMID:39811123]; target: "Therefore, starting from a PDE7A/7B dual inhibitor, our investigations led to improved selectivity along with extended metabolic stability, resulting in a novel PDE7A inhibitor 26." [PMID:39811123]; developer: "Chemical Research Laboratories, i2i-Labo, Biological Pharmacological Research Laboratories, and Drug Metabolism & Pharma-cokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco, Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan." [PMID:39811123]
02
Targets
PDE7A (Phosphodiesterase 7A)
Beyond the preview
Go deeper on Japan Tobacco PDE7A compound 26.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Japan Tobacco PDE7A compound 26.